^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Fallopian Tube Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Bevacizumab in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agent
Secondary therapy:
bisphosphonate bound paclitaxel; topotecan; pegylated liposomal doxorubicin
Source:
Excerpt:
Bevacizumab, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer
Secondary therapy:
carboplatin + paclitaxel
Source:
Excerpt:
Avastin is a vascular endothelial growth factor inhibitor indicated for the treatment of…Epithelial ovarian, fallopian tube, or primary peritoneal cancer…in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens
Secondary therapy:
topotecan; paclitaxel + pegylated liposomal doxorubicin
Source:
Excerpt:
Bevacizumab, in combination with carboplatin and gemcitabine, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer
Secondary therapy:
carboplatin + gemcitabine
Source:
Excerpt:
Avastin is a vascular endothelial growth factor inhibitor indicated for the treatment of:... Epithelial ovarian, fallopian tube, or primary peritoneal cancer:...in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for stage III or IV disease following initial surgical resection...in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens...in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by Avastin as a single agent, for platinumsensitive recurrent disease...
Secondary therapy:
carboplatin + gemcitabine; carboplatin + bisphosphonate bound paclitaxel
Source:
Excerpt:
Acceptable Recurrence Therapies for…Fallopian tube cancer: Preferred regimen...Carboplatin/Gemcitabine ± Bevacizumab...Carboplatin/Liposomal Doxorubicin ± Bevacizumab…Paclitaxel/Carboplatin/Bevacizumab...5-FU/Leucovorin/Oxaliplatin ± Bevacizumab…Capecitabine/Oxaliplatin ± Bevacizumab...Cyclophosphamide (oral)/Bevacizumab...Liposomal Doxorubicin/Bevacizumab...Paclitaxel (weekly)/Bevacizumab...Topotecan/Bevacizumab
Secondary therapy:
capecitabine + oxaliplatin; cyclophosphamide; 5-fluorouracil + oxaliplatin + leucovorin calcium; carboplatin + gemcitabine; topotecan; carboplatin + paclitaxel; carboplatin + pegylated liposomal doxorubicin; paclitaxel; pegylated liposomal doxorubicin
Source:
Excerpt:
Acceptable Recurrence Therapies for…Fallopian tube cancer: Targeted Therapy...Bevacizumab
Acceptable Recurrence Therapies for Epithelial Ovarian (including LCOC)/Fallopian Tube/Primary Peritoneal Cancer....Recurrence Therapy for Platinum-Resistant Disease….Other Recommended Regimens...Gemcitabine/bevacizumab
Primary Systemic Therapy Regimens - Epithelial Ovarian/Fallopian Tube/Primary Peritoneal….Useful in Certain Circumstances...Docetaxel/oxaliplatin/bevacizumab + maintenance bevacizumab (for stage IB/IC)
Secondary therapy:
gemcitabine; docetaxel + oxaliplatin
